Arcutis Biotherapeutics 株価情報 (NASDAQ: ARQT)

最新ニュース Arcutis Biotherapeutics (NASDAQ:ARQT) 株価情報

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

Full year preliminary production was above the midpoint of the tightened guidance range of 505,000 to 530,000 ounces, as announced in the third quarter 2024 results.

News

Eldorado Gold Reports Preliminary Gold Production Of 155,669 Ounces For Q4, And 520,293 Ounces For Full Year, Delivering 7% Annual Production Growth YoY

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is scheduled to release fourth-quarter earnings on Jan. 29. Ahead of the earnings report, Goldman Sachs shared its views on Meta&#8217;s earnings potential. Here&#8217;s what <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42986509/meta-platforms-announces-performance-based-job-cuts-whats-going-on">you need to know</a>. 
The Details: Goldman Sachs analyst Eric Sheridan maintained a Buy rating on Meta and raised the 12-month price target from $630 to $688 to reflect higher revenue estimates on the back of positive channel checks. 
The Goldman analyst highlighted the possibility for Meta to achieve compounded mid-teens revenue growth in the fourth quarter and sustain that momentum into 2025.
In the note, Sheridan pointed to several advertising opportunities to support his outlook, including the potential for Meta to boost advertising revenue by increasing ad load on Reels. The Goldman analyst also believes that Meta has yet to fully utilize WhatsApp and Messenger for ad revenue. 
Sheridan noted that Meta has significant untapped potential in areas such as click-to-message ads and paid messaging. The analyst also acknowledged the possibility of advertising dollars being redistributed to platforms like Meta if the Protecting Americans from Foreign Adversary Controlled Applications Act is upheld and TikTok is banned in the U.S.
&#8220;Based on our advertising checks, Meta continues to see strong momentum in its core advertising business and should drive above-industry topline growth over the next several quarters,&#8221; Sheridan said in the note.
See Also: <a href="https://www.benzinga.com/insights/options/25/01/42979541/looking-at-goldman-sachs-grs-recent-unusual-options-activity">Looking At Goldman Sachs Gr&#8217;s Recent Unusual Options Activity</a>
Additionally, the analyst sees upside potential for Meta from several long-term AI revenue opportunities, including sponsored search results within Meta AI conversations and licensing its Llama AI models for enterprise use. However, Sheridan noted that these products are early in their lifecycles, and better visibility into their development and adoption is needed before factoring them into forecasts as material revenue drivers.
&#8220;We see a path to Meta delivering toward the top end of its revenue guidance range for Q4'24 and sustained ~mid-teens % total revenue growth through 2025,&#8221; the Goldman analyst said.
Meta is due to report earnings after the market close on Jan. 29. Analysts expect the company to report earnings of $6.77 per share and revenue of about $47 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
META Price Action: Meta shares closed Tuesday down 2.31% at $594.25, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Earnings

Social Media

Price Target

Previews

Movers

Meta Platforms Analyst Expects 'Strong Momentum' In Q4 To Continue In 2025

Reported Earlier, John Deere Plans To Offer Centralized Platform For Self-Repair

The Los Angeles wildfires have killed at least two dozen people and destroyed thousands of homes, prompting questions of what&#8217;s to blame <a href="https://www.benzinga.com/news/legal/25/01/42953761/santa-ana-winds-return-as-la-wildfire-damage-estimates-rise-to-at-least-250-billion-fire-officials-investigate-downed-power-lines">for the blazes</a>.
A new Emerson College poll asks Americans if climate change contributed to the wildfires and whether California Gov. Gavin Newsom has done a good job handling the disaster.
What Happened: A new Emerson College <a href="https://emersoncollegepolling.com/january-2025-national-poll-democrats-republicans-and-independents-agree-u-s-is-on-the-wrong-track/">poll</a>, conducted Jan. 10 through Jan. 11, shows Americans are paying close attention to<a href="https://www.benzinga.com/general/sports/25/01/42889402/nhl-game-canceled-after-los-angeles-fires-nfl-monitoring-situation-ahead-of-monday-playoff-game"> the wildfires</a>. 
When respondents were asked how closely they are following the California wildfires news, these were the results:
<ul>
<li>Very Closely: 47.4%</li>
<li>Somewhat Closely: 39.5%</li>
<li>Not Very Closely: 9.7%</li>
<li>Not At All: 3.4%</li>
</ul>
The poll found that nearly half of Americans who responded are following the wildfire news closely, with around 87% saying they were either very closely or somewhat closely following the news.
Another question was around the potential causes of the fires.
"Do you think climate change has contributed to California's recent wildfires?&#8221; the poll asked. The results were divided by age, shown below:
<ul>
<li>Age 18-29: 74% Yes, 26% No</li>
<li>Age 30-39: 70% Yes, 31% No</li>
<li>Age 40-49: 61% Yes, 39% No</li>
<li>Age 50-59: 48% Yes, 52% No</li>
<li>Age 60-69: 49% Yes, 51% No</li>
<li>Age 70+: 53% Yes, 47% No</li>
</ul>
The poll found that in most cases the older a person was, the more likely they were to believe that climate change did not play a role in the fires.
Overall, 58% of Americans in the poll said that climate change has contributed to the wildfires and 42% said it has not.
The poll also showed a partisan split, with 85% of Democrats saying climate change contributed to the fires and 64% of Republicans saying climate change was not a factor. Independent voters were mostly split, with 54% saying climate change contributed to the wildfires.
Women were more likely to believe climate change was a contributing factor, with 64% saying yes versus 52% of men saying yes.
Read Also:<a href="https://www.benzinga.com/general/space/25/01/42939786/despite-elon-musks-feud-with-gavin-newsom-tesla-rolls-out-support-for-california-amid-wildfires-with-cybertrucks-starlink-and-megapack-chargers"> Despite Elon Musk&#8217;s Feud With Gavin Newsom, Tesla Rolls Out Support For California Amid Wildfires With Cybertrucks, Starlink And Megapack Chargers</a>
Newsom's Handling Of Disaster: The handling of the wildfires in California and the state's preparedness for such disasters has been a major talking point and drawn increased attention from President-elect Donald Trump and billionaire Elon Musk.
The poll asked Americans what they thought of Newsom's handling of the wildfires. These were the results:
<ul>
<li>Approve: 29.4%</li>
<li>Disapprove: 40.6%</li>
<li>Neutral: 26.7%</li>
</ul>
"The Governor's approval highlights sharp partisan divides in the perception of response: 61% of Republicans and 43% of Independents disapprove of Governor Newsom's response to the wildfires while 49% of Democrats approve," Emerson College Poll Executive Director Spencer Kimball said.
Newsom, a Democrat, was considered a potential replacement candidate in the 2024 election when President Joe Biden dropped out and is among the frontrunners in the <a href="https://www.benzinga.com/general/sports-betting/24/11/41830883/2028-election-betting-odds-where-do-j-d-vance-michelle-obama-mark-cuban-ron-desantis-kamal">betting odds for</a> the 2028 presidential election.
How Newsom handles the wildfires and his approval from Americans could be an early indicator of how he may fare in a presidential election if he chooses to run.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42933481/trump-vs-newsom-wildfire-war-escalates-as-california-faces-destruction">Trump vs. Newsom: Wildfire War Escalates as California Faces Destruction</a></li>
</ul>
Photo via Shutterstock.

Politics

Gavin Newsom's Crisis Management, Climate Change Impact On California Wildfires Covered In New Poll: What Americans Are Saying

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 8.92% on an annualized basis producing an average annual return of 20.08%. Currently, Masimo has a market capitalization of $8.93 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it would be worth $623.46 today based on a price of $166.95 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736892908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MASI

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Teresa Burchfield, the Company's Controller and former Chief Financial Officer, will take over &nbsp;White's duties on an interim basis until a successor Chief Financial Officer can be appointed.
 &nbsp;

Management

SIDU

On January 10, 2025, Sidus Space Terminated Employment Of CFO Bill White Without Cause - Filing

Legal

KKR Says It Filed Complaint Challenging Abuse Of Power And Unconstitutional Application Of HSR Act By The Antitrust Division Of DoJ; Also, Antitrust Division Filed Complaint Against KKR

Warner Bros. Discovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) shares are inching higher in extended trading Tuesday after the company added <a href="https://www.benzinga.com/pressreleases/25/01/n42990024/anthony-noto-and-joey-levin-to-join-warner-bros-discovery-inc-board-of-directors">two new board members</a>.
What Happened: After the market close on Tuesday, Warner Bros. Discovery announced that SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) CEO Anthony Noto and newly appointed Angi Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) Executive Chair Joey Levin were selected to join the company&#8217;s board.
&#8220;We are pleased to welcome two seasoned executives who will bring valuable insights and expertise to the board,&#8221; said&nbsp;David Zaslav, president and CEO of Warner Bros. Discovery.
&#8220;Both Anthony and Joey are accomplished leaders with considerable experience in relevant industries and exceptional track records of driving growth, innovation and shareholder value.&#8221;
Warner Bros. Discovery said Noto joined the board on Jan. 8, and Levin will join on Feb. 1. 
WBD Price Action: <a href="http://benzinga.com/quote/wbd">Warner Bros. Discovery shares</a> were up 1.13% after hours, trading at $9.84 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Don&#8217;t Miss: • <a href="https://www.benzinga.com/news/management/25/01/42962095/angi-shares-surge-as-iac-announces-spin-off-plans">Angi Shares Surge As IAC Announces Spin-Off Plans</a>
Photo: Shutterstock.

Entertainment

After-Hours Center

ANGI

SOFI

Warner Bros. Discovery Adds Anthony Noto, Joey Levin To Board, Shares Tick Higher

"Today I accepted Darren's resignation as he is pursuing another opportunity," said Chris Huskilson, Chief Executive Officer of AQN. "Darren will remain as CFO through the reporting of the Company's fourth quarter 2024 results."

Algonquin Power & Utilities Reports Upcoming Departure Of CFO Darren Myers; Company To Conduct Replacement Search

A <a href="https://www.benzinga.com/topic/tiktok">TikTok </a>post from an Ohio woman showing several weed buds found in her daughter's Burger King order has gone viral. The user, JannaBama, says she bought her daughter&#8217;s chicken fries at a drive-thru Sunday night at the Burger King in Hamilton. Once home, she unpacked the food order and found what looked like enough weed buds for several joints.
"I went to Burger King tonight. I got my kid some chicken fries,&#8221; she began on the video. &#8220;Listen, I need you guys to listen." She then held up the small empty bag where the chicken fries were packed and turned around to show the inside. "If you look in there, you can see some residue."
 &#8220;She got her chicken fries,&#8221; JannaBama said moving her camera down to show several cannabis buds in a plate. &#8220;Chicken fries with a side of, do you see that? You can&#8217;t say that on here… (TikTok). Mary Jane, from Burger King in Hamilton, Ohio.&#8221;
<figure class="wp-block-embed is-type-video is-provider-tiktok wp-block-embed-tiktok"> 
<div class="wp-block-embed__wrapper">
<blockquote class="tiktok-embed" cite="https://www.tiktok.com/@jannamichelle6/video/7458899714814250286" data-video-id="7458899714814250286" data-embed-from="oembed" style="max-width:605px; min-width:325px;"> <section> <a target="_blank" title="@jannamichelle6" href="https://www.tiktok.com/@jannamichelle6?refer=embed">@jannamichelle6</a>
Cannot make this up &#x1f633; !!! I didn't ask for a side of this @Burger King. <a title="ohio" target="_blank" href="https://www.tiktok.com/tag/ohio?refer=embed">#ohio</a> <a title="sideorder" target="_blank" href="https://www.tiktok.com/tag/sideorder?refer=embed">#sideorder</a> <a title="tiktokmademebuyit" target="_blank" href="https://www.tiktok.com/tag/tiktokmademebuyit?refer=embed">#tiktokmademebuyit</a> 
 <a target="_blank" title="♬ original sound - JannaBama" href="https://www.tiktok.com/music/original-sound-7458899700805192490?refer=embed">♬ original sound &#8211; JannaBama</a> </section> </blockquote>
<script async src="https://www.tiktok.com/embed.js"></script></div>
</figure>
"Cannot make this up," said the post caption. "I didn't ask for a side of this."
As of mid-afternoon on Jan. 14, JannaBama's video has over 150,00 views with over 100,00 likes.
Read Also: <a href="https://www.benzinga.com/general/social-media/25/01/42965533/elon-musk-emerges-as-potential-tiktok-us-buyer-as-ban-deadline-looms-company-terms-it-pure-fiction">Elon Musk Emerges As Potential TikTok US Buyer As Ban Deadline Looms, Company Terms It &#8216;Pure Fiction&#8217;</a>
<h1 class="wp-block-heading">Authorities Respond</h1>
&#8220;We contacted the Franchisee of this restaurant immediately upon learning of this incident and can confirm that the employee in question has been terminated,&#8221; a Burger King spokesperson told local media outlets.&nbsp;&#8220;We were very disappointed to learn of the incident and do not take incidents that put our guests in danger lightly.&#8221;
Hamilton police Sgt. Brian Ungerbuehler <a href="https://www.cincinnati.com/story/news/2025/01/14/burger-king-worker-fired-after-woman-finds-marijuana-with-childs-food/77694524007/">told</a> Cincinnati.com in an email that while no formal reports were made to the department, its officers are "actively investigating," the incident, adding that more information will be released once it becomes available.
<h1 class="wp-block-heading">TikTok&#8217;s Woes Are Far Worse Than Burger King&#8217;s</h1>
TikTok, which boasts over 170 million users in the U.S., is facing a <a href="https://www.benzinga.com/startups/24/12/42496518/tiktok-ban-signed-into-law-what-it-means-for-americas-15-billion-small-business-economy" target="_blank" rel="noreferrer noopener">law that threatens to block the social media app</a>. President-elect&nbsp;Donald Trump, meanwhile, <a href="https://www.benzinga.com/24/12/42712643/trump-asks-supreme-court-to-delay-tiktok-ban-as-he-pursues-a-political-resolution">is seeking </a>a &#8220;political resolution&#8221; to the TikTok ban. The Supreme Court has signaled support for enforcing the<a href="https://www.benzinga.com/24/12/42495579/lawmakers-demand-apple-and-google-remove-tiktok-by-jan-19-what-you-need-to-know" target="_blank" rel="noreferrer noopener">&nbsp;Jan. 19 deadline.</a>
Burger King is part of Restaurant Brands International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931704/tiktok-users-call-on-trump-to-deliver-immediately-on-his-promise-to-save-app-from-us-ban-we-dont-need-the-supreme-court-to">TikTok Users Call On Trump To &#8216;Deliver Immediately&#8217; On His &#8216;Promise&#8217; To Save App From US Ban: &#8216;We Don&#8217;t Need The Supreme Court To…&#8217;</a></li>
</ul>
Photo: Savvapanf on Shutterstock

Cannabis

Restaurants

Large Fries And Side Of Weed? TikTok Post From Woman Who Got Cannabis In Her Burger King Order Goes Viral

Guidance

Lotus Technology Aims To Increase 2025 Global Deliveries By 20% With 25-28% Contribution From China

Lotus Technology Reports Delivery Of 12,065 Vehicles In 2024, Representing YoY Increase Of Over 70%

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Franklin Resources, revealing an average target of $20.0, a high estimate of $22.50, and a low estimate of $18.50. Observing a downward trend, the current average is 2.2% lower than the prior average price target of $20.45. 
<img src="https://www.benzinga.com/files/images/story/2025/1736892058_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Franklin Resources among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.50</td>
<td>$19.50</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$18.50</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.50</td>
<td>$19.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Franklin Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Franklin Resources compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Franklin Resources's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Franklin Resources's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Franklin Resources analyst ratings.</a>
<h2>Unveiling the Story Behind Franklin Resources</h2>
Franklin Resources provides investment services for individual and institutional investors. At the end of October 2024, Franklin had $1.631 trillion in managed assets, composed primarily of equity (38%), fixed-income (32%), multi-asset/balanced (11%) funds, alternatives (15%) and money market funds (4%). Distribution tends to be weighted equally between retail investors (53% of AUM) and institutional accounts (45%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the us-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
<h3>Franklin Resources: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Franklin Resources's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Franklin Resources's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -4.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.74%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Franklin Resources's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.28%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Franklin Resources's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

11 Analysts Assess Franklin Resources: What You Need To Know

In the preceding three months, 6 analysts have released ratings for WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for WEX, presenting an average target of $203.33, a high estimate of $230.00, and a low estimate of $180.00. This current average represents a 12.17% decrease from the previous average price target of $231.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736892049_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of WEX among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WEX. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WEX compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of WEX's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of WEX's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WEX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WEX analyst ratings.</a>
<h2>All You Need to Know About WEX</h2>
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the largest segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Wex's largest end market is the United States of America.
<h3>Financial Milestones: WEX's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, WEX showcased positive performance, achieving a revenue growth rate of 2.16% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): WEX's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.95%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): WEX's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.73%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: WEX's debt-to-equity ratio surpasses industry norms, standing at 2.73. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into WEX Stock: Analyst Perspectives (6 Ratings)

5 analysts have expressed a variety of opinions on Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Terex and provided 12-month price targets. The average target is $55.6, accompanied by a high estimate of $65.00 and a low estimate of $48.00. Highlighting a 9.74% decrease, the current average has fallen from the previous average price target of $61.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1736892040_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Terex by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Terex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Terex compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Terex's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Terex's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TEX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Terex analyst ratings.</a>
<h2>Get to Know Terex Better</h2>
Terex is a top manufacturer of aerial work platforms, materials processing equipment, and specialty equipment, such as material handlers, cranes, and concrete mixer trucks. Its current composition is a result of numerous acquisitions over several decades and a recent shift to focus on its two core segments after divesting a handful of underperforming businesses. Terex's remaining segments see heavy demand in nonresidential construction as well as in maintenance, manufacturing, energy, and materials management.
<h3>Terex: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Terex's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -6.05% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Terex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.33%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Terex Through 5 Analysts

In the latest quarter, 8 analysts provided ratings for Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Crescent Energy and provided 12-month price targets. The average target is $17.62, accompanied by a high estimate of $21.00 and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 7.57% increase from the previous average price target of $16.38.
<img src="https://www.benzinga.com/files/images/story/2025/1736892029_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Crescent Energy's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crescent Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Crescent Energy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Crescent Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Crescent Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRGY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crescent Energy analyst ratings.</a>
<h2>Unveiling the Story Behind Crescent Energy</h2>
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
<h3>Crescent Energy's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Crescent Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.95% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Crescent Energy's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crescent Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.4%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Crescent Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.12%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Crescent Energy's debt-to-equity ratio stands notably higher than the industry average, reaching 1.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGY

Analyst Expectations For Crescent Energy's Future

In the last three months, 5 analysts have published ratings on KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for KKR Real Estate Finance, revealing an average target of $12.45, a high estimate of $13.50, and a low estimate of $11.50. Experiencing a 1.19% decline, the current average is now lower than the previous average price target of $12.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1736892023_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive KKR Real Estate Finance. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.25</td>
<td>$13.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Steven Delaney</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Stephen Laws</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to KKR Real Estate Finance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KKR Real Estate Finance compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of KKR Real Estate Finance's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into KKR Real Estate Finance's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KREF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KKR Real Estate Finance analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into KKR Real Estate Finance's Background</h2>
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
<h3>Key Indicators: KKR Real Estate Finance's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining KKR Real Estate Finance's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -3.96% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KKR Real Estate Finance's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -31.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): KKR Real Estate Finance's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.95%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): KKR Real Estate Finance's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 3.9, KKR Real Estate Finance adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KREF

What Analysts Are Saying About KKR Real Estate Finance Stock

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $470.25, along with a high estimate of $481.00 and a low estimate of $450.00. Witnessing a positive shift, the current average has risen by 10.91% from the previous average price target of $424.00.
<img src="https://www.benzinga.com/files/images/story/2025/1736892010_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bio-Rad Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$481.00</td>
<td>$481.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$481.00</td>
<td>$369.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$469.00</td>
<td>$446.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bio-Rad Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Rad Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Rad Laboratories's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Rad Laboratories analyst ratings.</a>
<h2>About Bio-Rad Laboratories</h2>
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
<h3>Breaking Down Bio-Rad Laboratories's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Bio-Rad Laboratories showcased positive performance, achieving a revenue growth rate of 2.79% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bio-Rad Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 100.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bio-Rad Laboratories's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bio-Rad Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bio-Rad Laboratories's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Bio-Rad Laboratories In The Eyes Of 4 Experts

The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026.

CNTX

Context Therapeutics Says First Patient Dosed In Its Phase 1 Clinical Trial Evaluating CTIM-76

CORRECTION: Ticker For Kennametal Is KMT

Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target of $20.00...

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

Mizuho raised the firm's price target on Arcutis Biotherapeutics (ARQT) to $20 from $19 and keeps an Outperform rating on the shares. The firm says...

Arcutis Biotherapeutics price target raised to $20 from $19 at Mizuho

2024 Performance Review And Future Strategy

Reports preliminary FY24 revenue $160M, consensus $180.61M. Preliminary unaudited cash, cash equivalents, restricted cash, and marketable securitie...

Arcutis Biotherapeutics reports preliminary Q4 revenue $63M, consensus $54.95M

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hologic (HOLX – Research Report) and Arcutis Bioth...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX) and Arcutis Biotherapeutics (ARQT)

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) yesterday and set a price target ...

Strong Financial Performance and Growth Prospects Drive Buy Rating for Arcutis Biotherapeutics

In a report released today, Serge Belanger from Needham maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a price t...

Arcutis Biotherapeutics: Strong Sales and Strategic Growth Drive Buy Rating

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price ...

Arcutis Biotherapeutics' Robust Revenue Growth and Strategic Financial Positioning Underpin Buy Rating

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target of $20.00...

TD Cowen Remains a Buy on Arcutis Biotherapeutics (ARQT)

Needham analyst Serge Belanger raised the firm's price target on Arcutis Biotherapeutics (ARQT) to $20 from $18 and keeps a Buy rating on the share...

Arcutis Biotherapeutics price target raised to $20 from $18 at Needham

AMGN

ARQT

CRSP

GILD

HOLX

KRYS

KURA

NTLA

SDGR

SMMT

TEVA

TSLA

VKTX

VRTX

VTRS

Press Releases

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Health Care

General

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

Arcutis Announces Promotions on Executive Management Team

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Comments

Arcutis Biotherapeutics

ニュース

最新ニュース Arcutis Biotherapeutics (NASDAQ:ARQT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル